Altimmune Files 8-K on Financials
Ticker: ALT · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Altimmune dropped an 8-K on financials, check it for the latest numbers.
AI Summary
Altimmune, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Altimmune is providing updates on its financial status and operational results to the SEC, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial information and does not inherently signal new risks.
Key Players & Entities
- Altimmune, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 20-2726770 (other) — IRS Employer Identification No.
- 910 Clopper Road, Suite 201S (address) — Principal Executive Offices
- Gaithersburg, Maryland (location) — Principal Executive Offices Location
- 20878 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but it does not contain the specific details of these results or statements.
When was this 8-K filing submitted to the SEC?
The filing was submitted on August 12, 2025.
What is Altimmune, Inc.'s principal executive office address?
Altimmune, Inc.'s principal executive offices are located at 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is Altimmune, Inc.'s IRS Employer Identification Number?
Altimmune, Inc.'s IRS Employer Identification Number is 20-2726770.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-08-12 07:10:10
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar
Filing Documents
- alt-20250812x8k.htm (8-K) — 42KB
- alt-20250812xex99d1.htm (EX-99.1) — 178KB
- alt-20250812xex99d1002.jpg (GRAPHIC) — 7KB
- 0001558370-25-011145.txt ( ) — 372KB
- alt-20250812.xsd (EX-101.SCH) — 3KB
- alt-20250812_lab.xml (EX-101.LAB) — 18KB
- alt-20250812_pre.xml (EX-101.PRE) — 13KB
- alt-20250812x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 12, 2025, Altimmune, Inc. (the "Company") issued a press release announcing the Company's financial results for its second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits No. Description 99.1 Press Release of Altimmune, Inc. dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTIMMUNE, INC. By: /s/ Gregory Weaver Name: Gregory Weaver Title: Chief Financial Officer Dated: August 12, 2025